Your browser doesn't support javascript.
loading
Cooperative pro-tumorigenic adaptation to oncogenic RAS through epithelial-to-mesenchymal plasticity.
De Blander, Hadrien; Tonon, Laurie; Fauvet, Frédérique; Pommier, Roxane M; Lamblot, Christelle; Benhassoun, Rahma; Angileri, Francesca; Gibert, Benjamin; Rodriguez, Raphaël; Ouzounova, Maria; Morel, Anne-Pierre; Puisieux, Alain.
Affiliation
  • De Blander H; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue Contre le Cancer, 69008, Lyon, France.
  • Tonon L; LabEx DEVweCAN, Université de Lyon, F-69000, Lyon, France.
  • Fauvet F; Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.
  • Pommier RM; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue Contre le Cancer, 69008, Lyon, France.
  • Lamblot C; LabEx DEVweCAN, Université de Lyon, F-69000, Lyon, France.
  • Benhassoun R; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue Contre le Cancer, 69008, Lyon, France.
  • Angileri F; LabEx DEVweCAN, Université de Lyon, F-69000, Lyon, France.
  • Gibert B; Synergie Lyon Cancer, Plateforme de Bioinformatique 'Gilles Thomas', Centre Léon Bérard, Lyon, France.
  • Rodriguez R; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue Contre le Cancer, 69008, Lyon, France.
  • Ouzounova M; LabEx DEVweCAN, Université de Lyon, F-69000, Lyon, France.
  • Morel AP; Cancer Research Center of Lyon, Université de Lyon, Université Claude Bernard Lyon 1, INSERM 1052, CNRS 5286, Centre Léon Bérard, Equipe Labellisée Ligue Contre le Cancer, 69008, Lyon, France.
  • Puisieux A; LabEx DEVweCAN, Université de Lyon, F-69000, Lyon, France.
Sci Adv ; 10(7): eadi1736, 2024 Feb 16.
Article in En | MEDLINE | ID: mdl-38354248
ABSTRACT
In breast cancers, aberrant activation of the RAS/MAPK pathway is strongly associated with mesenchymal features and stemness traits, suggesting an interplay between this mitogenic signaling pathway and epithelial-to-mesenchymal plasticity (EMP). By using inducible models of human mammary epithelial cells, we demonstrate herein that the oncogenic activation of RAS promotes ZEB1-dependent EMP, which is necessary for malignant transformation. Notably, EMP is triggered by the secretion of pro-inflammatory cytokines from neighboring RAS-activated senescent cells, with a prominent role for IL-6 and IL-1α. Our data contrast with the common view of cellular senescence as a tumor-suppressive mechanism and EMP as a process promoting late stages of tumor progression in response to signals from the tumor microenvironment. We highlighted here a pro-tumorigenic cooperation of RAS-activated mammary epithelial cells, which leverages on oncogene-induced senescence and EMP to trigger cellular reprogramming and malignant transformation.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cell Transformation, Neoplastic / Carcinogenesis Limits: Humans Language: En Journal: Sci Adv Year: 2024 Document type: Article Affiliation country: France

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Cell Transformation, Neoplastic / Carcinogenesis Limits: Humans Language: En Journal: Sci Adv Year: 2024 Document type: Article Affiliation country: France